Home > Insider Trading > Filing (0001127602-12-020807)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
850693	Allergan Inc	AGN	Pharmaceutical Preparations (2834)	951622442

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1298861	M Trevor Jones	2525 Dupont Drive Irvine CA 92612		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2012-06-26	1,500	$90.00	21,827	No	4	S	Direct
Common Stock	Acquisiton	2012-06-26	1,000	$60.60	22,827	No	4	M	Direct
Common Stock	Disposition	2012-06-26	1,000	$90.06	21,827	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Nonemployee Director Stock Option (Right to Buy)	Disposition	2012-06-26	1,000	$0.00	1,000	$60.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
10,400		2017-05-01	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 10, 2012.
The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $89.99 to $90.0052, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $90.06 to $90.09, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Includes 4,800 shares of the Issuer's common stock underlying the RSUs awarded.
Includes shares issued pursuant to the dividend equivalent rights, exempt transaction under Rule 16a-11.
Option is fully vested and exercisable on the date of the next regular annual meeting of stockholders of Allergan, Inc. at which directors are to be elected following the date of grant.